Helicobacter pylori

Scandinavian Journal of Gastroenterology

Volumn 30, Issue S208, 1995, Pages 33-46

  Lambert, J R ^a   Lin, S K ^a   Aranda Michel, J ^a  

^a PENINSULA HEALTH   (Australia)

Author keywords

Epidemiology; Helicobacter pylori; Pathogen mechanisms; Treatment

Indexed keywords

ANIMAL; DISEASE TRANSMISSION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MICROBIOLOGY; PATHOPHYSIOLOGY; REVIEW; STOMACH DISEASE; GASTRITIS; NONHUMAN; PRIORITY JOURNAL; STOMACH CANCER; STOMACH ULCER;

ANIMAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMAN; STOMACH DISEASES;

AMOXICILLIN; BISMUTH CITRATE; BISMUTH SALICYLATE; CLARITHROMYCIN; LANSOPRAZOLE; METRONIDAZOLE; OMEPRAZOLE; RANITIDINE; TINIDAZOLE;

EID: 0028914646     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365529509107760     Document Type: Article

References (191)

1. The genesis of coccal forms of H. pylori in H. pylori gastritis and peptic ulcer
2. Coccoid forms of H. pylori are viable
3. Characterization of 'Campylobacter pyloridis' by culture, enzymatic profile, and protein content
4. Helicobacter pylori catalase
5. Unusual fatty acid substitution in lipids and lipopolysaccharides of Helicobacter pylori
6. The absence of thermoplasmaquinones in Campylobacter pyloridis and its temperature and pH growth range
7. Surface morphology of the gastroduodenal mucosa in duodenal ulceration
8. Campylobacter pyloridis and acid induced gastric metaplasia in the pathogenesis of duodenitis
9. Epithelial morphology of duodenal bulb and campylobacter-like organisms
10. Campylobacter pylori and Barrett's esophagus
11. Gastric and esophageal Campylobacter pylori in patients with Barrett's esophagus
12. Campylobacter pylori and Barrett's esophagus
13. Campylobacter-like organism and heterotopic gastric mucosa in Meckel's diverticula
14. Gastritis in the rectum: Campylobacter-like organisms in heterotopic inflamed gastric mucosa
15. Local immune response to gastric Campylobacter in non-ulcer dyspepsia
16. Systemic and local antibody responses to gastric Campylobacter pyloridis in non-ulcer dyspepsia
17. Campylobacter pyloridis and gastritis: association with intercellular spaces and adaptation to an environment of mucus as important factors in colonization of the gastric epithelium
18. Pathogenetic implications of ultrastructural findings in Campylobacter pylori related gastroduodenal disease
19. Campylobacter-like organisms in the stomach of patients and healthy individuals
20. Campylbacter pyloridis, urease, hydrogenion back diffusion, and gastric ulcers
21. Essential role of urease in pathogenesis of gastritis induced by Helicobacter pylori in gnotobiotic piglets
22. Campylobacter pylori and duodenal ulcers: the gastrin link
23. Effect of increasing Helicobacter pylori ammonia production by urea infusion on plasma gastrin concentration
24. Effect of inhibition of H. pylori urease activity by acetohydroxamic acid on serum gastrin in duodenal ulcer subjects
25. + moving through gastric mucus
26. + Ion-exchange property of postmortem human gastric mucus. The effects of Campylobacter pylori infection and sucralfate
27. Effect of ammonia on the gastric mucosa in rats: pathophysiological importance of urease in gastric ulcer disease
28. Campylobacter pyloridis gastritis I: Detection of urease as a marker of bacterial colonization and gastritis
29. Effect of ammonium on bacteria adherence to bladder transitional epithelium
30. Surface proteins from Helicobacter pylori exhibit chemotactic activity for human leukocytes and are present in gastric mucosa
31. Cytotoxic activity in broth-culture filtrates of Campylobacter pylori
32. Cytotoxin production by H. pylori more common in peptic ulcer disease
33. Campylobacter pylori virulence factors in gnotobiotic piglets
34. Cytotoxin production by Campylobacter pylori strains isolated from patients with peptic ulcers and from patients with chronic gastritis only
35. Characterization of human serologic response to proteins in Helicobacter pylori broth culture supernatants with vacuolizing cytotoxin activity
36. Helicobacter pylori vacuolating toxin
37. Inhibition of acid secretion from parietal cells by non-human-infecting Helicobacter species: a factor in colonization of gastric mucosa?
38. Effect of a Campylobacter pylori protein on acid secretion by parietal cells
39. Lipolytic activity of Campylobacter pylori, effect of sofalcone
40. Different effect of Helicobacter pylori on the human gastric antral and body mucosal intracellular mucin
41. Adherence and internalization of Helicobacter pylori by HEP-2 cells
42. Evidence for gastric mucosal cell invasion by C. pylori: an ultrastructural study
43. Adherence of Helicobacter pylori cells and their surface components to HeLa cell membranes
44. Characterization of the Helicobacter pylori urease and purification of its subunits
45. Production of a conserved adhesin by the human gastroduodenal pathogen Helicobacter pylori
46. N-acetylneuraminyllactose-binding fibrillar hemagglutinin of Campylobacter pylori: a putative colonization factor antigen
47. An ELISA technique for the serodiagnosis of Campylobacter pyloridis infection in patients with gastritis and benign duodenal ulceration
48. Antibody to Campylobacter pylori in families of index children with gastrointestinal illness due to C. pylori [letter]
49. Campylobacter pylori antibodies in humans
50. The B-cell immune response to Helicobacter pylori
51. Overview of the immune response to Helicobacter pylori
52. T-Cell subsets: responses to Helicobacter pylori
53. Mucosal IgA recognition of H. pylori 120 kDa protein, peptic ulceration and gastric pathology
54. Inhibition of gastric mucosal laminin receptor by Helicobacter pylori lipopolysaccharide
55. Ribotyping of Helicobacter pylori from clinical specimens
56. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race and socioeconomic status
57. Seroepidemiology of Campylobacter pyloridis
58. Seroepidemiology of Campylobacter pylori infection in various populations
59. Campylobacter pylori in Swedish patients referred for gastroscopy
60. Studies of the epidemiology of peptic ulcer in a rural community: prevalence and natural history of dyspepsia and peptic ulcer
61. Comparison of Helicobacter pylori in three ethnic groups—evidence for oral-oral transmission
62. High prevalence of Helicobacter pylori antibodies in institutionalized adults
63. The cohort effect and Helicobacter pylori
64. Epidemiology of Helicobacter pylori in Southern China: identification of early childhood as the critical period for acquisition
65. Symptoms and risk factors of Helicobacter pylori infection in a cohort of epidemiologists
66. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population
67. Prevalence of Helicobacter pylori in a representative Anglo-Celtic population of urban Melbourne
68. Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic persons
69. Age-dependent increase of Campylobacter pylori antibodies in blood donors
70. Antibody response to Campylobacter pylori in an ethnic group lacking peptic ulceration
71. Seroprevalence of Helicobacter pylori infections in Thailand
72. Serologic response to Helicobacter pylori among children and teenagers in northern Chile
73. Factors influencing the epidemiology of Helicobacter pylori in children
74. Prevalence of Helicobacter (formerly Campylobacter) pylori infection in Saudia Arabia, and comparison of those with and without upper gastrointestinal symptoms
75. Childhood living conditions and Helicobacter pylori seropositivity in adult life
76. Campylobacter pylori in peptic ulcer disease. III: Symptoms and paraclinical and epidemiologic findings
77. Cigarette smoking and Helicobacter pylori infection
78. Effect of alcohol consumption on the risk of Helicobacter pylori infection
79. Long-term non-steroidal anti-inflammatory drug use and gastroduodenal injury: the role of Helicobacter pylori
80. Social and geographical risk factors in Helicobacter pylori infection
81. Seroepidemiology of Helicobacter pylori infection in vegans and meateaters
82. Seroprevalence of Helicobacter pylori in Chile: vegetables may serve as one route of transmission
83. Effect of ABO blood group and secretor status on the frequency of Helicobacter pylori antibodies
84. Isolation of a gastric Campylobacter-like organism from the stomach of four rhesus monkeys, and identification as Campylobacter pylori
85. Campylobacter-like organisms in the gastric mucosa of rhesus monkeys
86. Campylobacter pylori isolated from the stomach of the monkey, Macaca nemestrina
87. Isolation of Campylobacter pylori from the stomach of Cynomolgus monkeys and experimental infection of the cynomolgus monkeys with the organisms
88. Spiral organisms in the baboon stomach
89. Helicobacter pylori isolated from the domestic cat; public health implication
90. Campylobacter pylori in abattoir workers: is it a zoonosis?
91. Prevalence of Helicobacter pylori in abattoir workers
92. Seroprevalence of Helicobacter pylori in seventh-day adventists and other groups in Maryland. Lack of association with diet
93. Ingestion of Campylobacter pyloridis causes gastritis and raised fasting gastric pH
94. Attempt to fulfil Koch's postulates for pyloric Campylobacter
95. Water source as risk factor for Helicobacter pylori infection in Peruvian children
96. Epidemiology of Helicobacter pylori infection
97. Person-to-person transmission of Campylobacter pylori [letter]
98. Elevated risk of Helicobacter pylori infection in submarine crews
99. Increased incidence of Campylobacter pylori infection in gastroenterologists: further evidence of support person-to-person transmission of C. pylori
100. Helicobacter pylori prevalence in endoscopy and medical staff
101. Transmission of Helicobacter pylori infection. Studies in families of healthy individuals
102. Intrafamilial clustering of Helicobacter pylori infection
103. Helicobacter pylori infection in families—evidence for person-to-person transmission
104. Restriction endonuclease analysis of the genome of Campylobacter pylori with a rapid extraction method: evidence for considerable genomic variation
105. Familial clustering of peptic ulcer disease colonized with C. pylori of the same DNA composition
106. Typing of Campylobacter pylori by bacterial DNA restriction endonuclease analysis and determination of plasmid profile
107. Detection of Helicobacter pylori by using the polymerase chain reaction
108. Identification of Helicobacter pylori DNA in the mouths and stomachs of patients with gastritis using PCR
109. Detection of Helicobacter pylori in dental plaque by reverse transcription-polymerase chain reaction
110. Isolation of Helicobacter pylori from dental plaques in healthy volunteers
111. Examination of human stomach biopsies, saliva, and dental plaque for Campylobacter pylori
112. H. pylori in dental plaques
113. H. pylori in dental plaques
114. Helicobacter pylori in dental plaque
115. Isolation of Helicobacter pylori from human feces
116. PCR identification of Helicobacter pylori in feces from gastritis patients
117. Detection of vacuolating toxin of Helicobacter pylori in human feces
118. Comparison of Helicobacter pylori prevalence in practising dental staff and gastroenterologists
119. Helicobacter pylori infection in dental workers: a seroepidemiology study
120. Characterization of risk factors for Helicobacter pylori infection among men attending a sexually transmitted disease clinic: lack of evidence for sexual transmission
121. Iatrogenic Campylobacter pylori infection is a cause of epidemic achlorhydria
122. Patient-to-patient transmission of Campylobacter pylori infection by fiberoptic gastroduodenoscopy and biopsy
123. Helicobacter pylori may be transmitted through gastrofiberscope even after manual Hyamine washing
124. Pyloric Campylobacter infection and gastroduodenal disease
125. Campylobacter pylori —a role in non-ulcer dyspepsia?
126. Campylobacter pylori in patients with gastritis, peptic ulcer, and carcinoma of the stomach in Lanzhou, China [Letter]
127. Prevalence of Campylobacter pylori and association with antral mucosal histology in subjects with and without upper gastrointestinal symptoms
128. Campylobacter pylori in Japan: bacteriological feature and prevalence in healthy subjects and patients with gastroduodenal disorders
129. Campylobacter-like organisms in patients with gastric ulcer
130. Campylobacter-like organisms in chronic gastritis, peptic ulcer, and gastric carcinoma
131. Campylobacter -associated gastritis in patients with non-ulcer dyspepsia
132. Campylobacter pyloridis -associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment
133. Prevalence of Campylobacter pylori in an unselected Swedish population of patients referred for gastroscopy
134. Prevalence of Campylobacter pylori in esophagitis, gastritis, and duodenal disease
135. Campylobacter pylori: associations with antral and fundic mucosal histology and diagnosis by serology in patients with upper gastrointestinal symptoms
136. The role of Helicobacter pylori in non-ulcer dyspepsia: a debate for Gastroenterol
137. Ofloxacin in the therapy of Campylobacter pylori -positive duodenal ulcer-a prospective controlled randomized study
138. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori
139. Ablation of exaggerated meal-stimulated gastrin release in duodenal ulcer patients after clearance of Helicobacter (Campylobacter) pylori infection
140. Effect of colloidal bismuth (DeNol) on healing and relapse of duodenal ulcer-role of C. pyloridis
141. Results of treatment of Helicobacter pylori infection in the recurrence of gastritis or duodenal ulcers: a randomized single-blind, single center study
142. DeNol plus oxacillin vs ranitidine and oxacillin in H.p. -positive duodenal ulcers: effects on relapse
143. Effect of Helicobacter pylori on gastric mucosal blood flow
144. Lowered gastrin and gastric acidity after eradication of Campylobacter pylori in duodenal ulcer [Letter]
145. Neutrophilactivation by Helicobacter pylori
146. Possible role of leukotrienes in gastritis associated with Campylobacter pylori
147. Antral mucosal gastrin and tumour necrosis factor-alpha release in patients with non-ulcer dyspepsia and H. pylori infection
148. Paf-acether synthesis by Helicobacter pylori
149. Antral gastrin and somatostatin cells in Helicobacter pylori subjects: restitution of D-cell number with eradication
150. Helicobacter pylori infection causes low antral somatostatin content: pathogenesis of inappropriate hypergastrinemia
151. Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease
152. Stimulation of gastrin release from cultured canine G-cells by Helicobacter pylori and mononuclear cells
153. Effect of tumour necrosis factor-alpha and bombesin on antral mucosal gastrin and somatostatin: influence of H. pylori infection
154. Eradicating H. pylori lowers gastrin-mediated acid secretion by 70% in DU patients and by 50% in healthy volunteers
155. Gastrin release and acid secretion are a critical function of H. pylori infection
156. Campylobacter pylori NSAIDs and smoking risk factors for peptic ulcer disease
157. Helicobacter pylori: a risk and severity factor in NSAIDs induced gastropathy
158. Helicobacter pylori infection, upper gastrointestinal (UGI) symptoms and blood loss in patients with rheumatoid arthritis on NSAID
159. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer—a randomized controlled study
160. Campylobacter pylori -associated gastritis and immune response in a population at increased risk of gastric carcinoma
161. Helicobacter pylori and gastric cancer
162. Helicobacter pylori -associated gastritis and primary B-cell gastric lymphoma
163. The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori
164. Helicobacter pylori-associated gastric lymphoma
165. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori
166. Follow-up study of individuals with untreated Campylobacter pylori -associated gastritis and of non-infected persons with non-ulcer dyspepsia
167. Long-term Helicobacter pylori recurrence after successful eradication with triple therapy
168. Duodenal ulcer treated with Helicobacter pylori eradication: seven-year follow-up
169. Molecular techniques for studying the epidemiology of infection by Helicobacter pylori
170. DNA fingerprints of Helicobacter pylori from mouth and antrum of patients with chronic ulcer dyspepsia
171. A comparison of diagnostic tests to determine Helicobacter pylori infection
172. Detection of antibody in saliva as an aid to management in Helicobacter pylori infection
173. Detection of immunoglobulin G-antibodies to Helicobacter pylori in urine by an enzyme immunoassay method
174. Helicobacter pylori therapy randomized study of DeNol/ antibiotic combinations. In Rev Esp Enf Dig
175. Combined therapy with ofloxacin and amoxicillin in the eradication of Helicobacter pylori
176. Short-term double drug Helicobacter pylori treatment: one week amoxicillin + tinidazole versus amoxicillin + nitrofurantoin
177. Evaluation of four short-term amoxicillin/tinidazole regimens for eradication of Helicobacter pylori. In Rev Esp Enf Dig
178. Omeprazole and amoxicillin in patients with duodenal ulcer: Helicobacter pylori eradication and remission of ulcers and symptoms during a 6 months' following. A double-blind comparative study
179. High-dose omeprazole treatment combined with amoxicillin eradication Helicobacter pylori
180. Helicobacter pylori treatment of gastritis
181. Oral triple therapy may effectively eradicate Campylobacter pylori in man: a pilot study
182. Controlled study of omeprazole-amoxicillin-tinidazole vs ranitidine-amoxicillin-tinidazole in Helicobacter pylori -associated duodenal ulcer (DU): final and long-term results
183. High efficacy low-dose triple therapy (TT) for Helicobacter pylori
184. Eradication of Campylobacter pylori infection with bismuth subsalicylate and antibiotic combinations
185. Amoxicillin and metronidazole in the eradication of Campylobacter pylori
186. Enhanced amoxicillin uptake into the human gastric mucosa at lower gastric juice pH
187. Lansoprazole, a novel benizimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori
188. Helicobacter pylori eradication with doxycycline-metronidazole-bismuth subcitrate triple therapy